Logo

Jazz Pharmaceuticals Acquires Redx Pharma's Pre-clinical Pan-RAF Inhibitor Program for RAF and RAS Mutant Tumors

Share this

Jazz Pharmaceuticals Acquires Redx Pharma's Pre-clinical Pan-RAF Inhibitor Program for RAF and RAS Mutant Tumors

Shots:

  • Redx to receive $3.5M up front- up to $203M as milestone & royalties on sales and will be responsible for pre-clinical activities of the program under a separate collaboration agreement with Jazz. Jazz to get rights to develop & commercialize Pan-RAF program and is responsible for its regulatory activities
  • The focus of the acquisition is to robust Jazz’s R&D portfolio of early-stage hematology/oncology therapies with the advancement of Redx’s pan-RAF inhibitor program- a precision oncology therapies
  • The preclinical results of the pan-RAF program demonstrated in-vivo efficacy in a B-RAFV600E mutant colorectal cancer xenograft model as monothx. with promising activity in RAS-mutated cancer

Click here to read full press release/ article | Ref: Jazz Pharmaceutical | Image: GMP News


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions